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A better understanding of how dietary lipids are processed by the human body is
necessary to allow for the control of satiation and energy intake by tailored lipid systems.
To examine whether rats are a valid model of human dietary lipid processing and
therefore useful for further mechanistic studies in this context, we tested in rats three lipid
emulsions of different stability, which alter satiety responses in humans. Different sets of
15 adult male Sprague Dawley rats, equipped with gastric catheters alone or combined
with hepatic portal vein (HPV) and vena cava (VC) catheters were maintained on a
medium-fat diet and adapted to an 8 h deprivation/16 h feeding schedule. Experiments
were performed in a randomized cross-over study design. After gastric infusion of the
lipid emulsions, we assessed gastric emptying by the paracetamol absorption test and
recorded in separate experiments food intake and plasma levels of gastrointestinal
hormones and metabolites in the HPV. For an acid stable emulsion, slower gastric
emptying and an enhanced release of satiating gastrointestinal (GI) hormones were
observed and were associated with lower short-term energy intake in rats and less
hunger in humans, respectively. The magnitude of hormonal responses was related to
the acid stability and redispersibility of the emulsions and thus seems to depend on
the availability of lipids for digestion. Plasma metabolite levels were unaffected by the
emulsion induced changes in lipolysis. The results support that structured lipid systems
are digested similarly in rats and humans. Thus unstable emulsions undergo the same
intragastric destabilization in both species, i.e., increased droplet size and creaming.
This work establishes the rat as a viable animal model for in vivo studies on the control
of satiation and energy intake by tailored lipid systems.
Keywords: lipid emulsion systems, fat digestion, animal model, gastric emptying, gastrointestinal hormones,
satiation, energy intake
INTRODUCTION
Lipids are the most energy-dense macronutrients. Their overconsumption along with high sodium,
sugar, and carbohydrate diets is associated with obesity, diabetes, and cardiovascular disease
(1–3). A better understanding of how dietary lipids, also in relationship to carbohydrates and
proteins, are processed in the human body may assist in the tailoring of lipid systems, which
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have the potential to modulate satiation and energy intake.
Lipid digestion takes place in both the stomach and small
intestine. It consists of the cleavage of the main lipid component,
triacylglycerol (TAG) into monoglycerides and free fatty acids
(FFA) (4). The presence of these lipid breakdown products
in the stomach and the small intestine triggers the release of
satiating hormones such as cholecystokinin (CCK), peptide YY
(PYY), and glucagon-like peptide-1 (GLP-1) and the release
of bile from the gall bladder (5–8). As these hormones also
affect gastric emptying, a closed feedback loop for the control
of fat digestion and absorption can be established. Most dietary
lipids are ingested in the form of oil-in-water emulsions or
so called lipid emulsions (LE), in which liquid oil or partially
solid fat is dispersed in water (9). The ability to modify
lipid digestive processing and satiation by the control of acid
stability and redispersibility of the LEs has recently attracted
attention (9–11).
Magnetic resonance imaging (MRI) studies in healthy
subjects demonstrated that acid unstable LEs form oil layers
in the upper stomach (12–14). This layering is associated
with delayed gastric emptying of the lipid phase into the
duodenum (15). Recent human studies addressed short-term
effects of LEs on eating behavior, including the effect of
intragastric LE administration on plasma CCK (16–19), active
GLP-1 (17) and total PYY (19, 20). However, with oral
ingestion of LEs mainly data for CCK are available (20–22).
The lack of longer-term studies assessing both changes in
eating behavior and GI hormones in humans is largely due
to the large costs of such studies (23), associated practical
limitations and high inter-individual variations. Therefore, a
reliable animal model is required to assist in streamlining
the development of targeted therapeutic LEs. In addition to
cost saving this streamlined process may also reduce risk
including adverse events to humans participating in oral
application studies.
Beside pigs, rats are the most commonly used animal model
for human fat digestion. Previous studies with rats addressed
the effect of intragastric LE administration on eating behavior
and plasma GLP-1 (24, 25), and PYY (24, 26–28). However,
it remained unclear whether these findings can be related
to humans. In addition, the absence of a gall bladder and
gastric lipase may impede direct comparison of rat and human
data (29).
In the present study in rats, we tested LEs that were previously
shown to alter satiation-mediating responses in humans (30).
We assessed the emulsions’ effects on gastric emptying, short-
term energy intake, and hepatic portal vein plasma levels
of total PYY, active GLP-1 as well as TAG and compared
them with human data. The aim was to examine whether the
rat presents a viable animal model of human lipid digestion
and processing.
MATERIALS AND METHODS
All procedures were approved by the local Veterinary Office
(Protocol No. 233-2012).
TABLE 1 | Composition and physical properties of the three lipid emulsions
infused and consumed by rats and humans (LE1, LE3, and LE4 are lipid emulsion
1, 3, and 4, MG is monoglyceride, NaCas is sodium caseinate, *30% of the fat
was hydrogenated rapeseed oil consisting of 25% solid fat and 75% liquid fat).
LE1 LE3 LE4
Fat content, weight percent 20 20 20
Fat consistency Liquid Solid + liquid* Liquid
Emulsifier type Polysorbate 80 NaCas + MG NaCas + MG
Emulsifier amount, weight percent 0.8 1 + 0.25 1 + 0.25
Thickener type Xanthan None None
Thickener amount, weight percent 0.4
Mean particle size, D4,3µm 0.33 0.32 0.38
Acid stabile Yes No No
Redispersible Yes No Yes
Lipid Emulsions and Layout of the Animal
Studies
Fifteen adult male Sprague Dawley rats (age: 10–12 weeks,
body weight: 400–500 g) were maintained on a medium-fat diet
(30 kJ% fat) and adapted to a 16 h feeding 8 h deprivation
schedule. The rats were equipped with hepatic portal vein (HPV),
vena cava (VC) and gastric catheters. Surgeries were performed
under Xylyzine/Ketamine anesthesia (4.5mg Xylazine and 90mg
Ketamine intraperitoneally per kg body weight) (31, 32). The
study was performed in a randomized cross-over design.
Three isocaloric (1.9 kcal/mL) LEs differing in acid stability,
fat source, and redispersibility were intragastrically infused as
single meals. The different properties and preparation schemes
of the previously validated LEs are summarized in Table 1 and
discussed in more detail in Steingoetter et al. and Golding et al.
(14, 33). In brief, LE1 is a small-droplet acid stable emulsion.
LE3 and LE4 are small-droplet acid unstable emulsions that differ
from each other in their solid fat content and thus redispersibility
of fat. After infusing the emulsions, gastric emptying was
measured by the paracetamol absorption test and recorded food
intake as well as postprandial profiles of metabolites and GI
hormones in separate experiments (34).
Gastric Emptying and Food Intake
Gastric emptying and food intake were recorded in the 15 rats
using the gastric catheters only. The rats were once food deprived
for an additional 2 h at the onset of their 16 h feeding period
and infused with 4mL of the LEs labeled with 1% paracetamol
(40 mg/4mL). Each rat received two different LEs. Type and
order of LE administration were randomized such that each LE
combination was tested in five different animals. Paracetamol was
measured in plasma from tail nick blood samples collected at
baseline (0min) and at 30, 60, 90, and 120min after emulsion
infusion. LE infusion days were separated by 2 washout days on
which saline was infused.
For food intake measurements, the rats deprived of food for
8 h were infused with one of the three LEs 30min immediately
prior dark onset, when the 16 h food access period started.
Cumulative food intake (±0.1 g) was recorded at 1, 2, 4, 6, and
Frontiers in Nutrition | www.frontiersin.org 2 November 2019 | Volume 6 | Article 170
Steingoetter et al. Rat Model of Lipid Digestion
16 h after infusion. Following a cross-over study design, all three
LEs were tested in all rats at two different doses of 4 and 8mL.
In addition, each animal (except two) were assigned one repeated
intervention. This way 43 animal food intakes were collected in
total. LE infusion days were separated by one washout day.
Plasma Concentrations of Metabolites and
Gastrointestinal Hormones
For plasma concentration of metabolites and gastrointestinal
hormone profiles the hepatic portal vein (HPV) and vena cava
(VC) catheters in addition to the gastric catheter were used
after emulsion infusion. Using the same protocol as for the
paracetamol absorption test, the rats received the LE infusions,
and HPV as well as VC blood was taken in parallel at baseline
(0min) and at 15, 30, 45, 60, and 120min after emulsion infusion.
Biochemical Analysis
Plasma paracetamol concentration was analyzed with the test kit
from Cambridge Life Sciences Ltd, UK. Plasma concentrations
of active GLP-1 and total PYY were measured by an electro-
chemiluminescence assay (MESO Scale Discovery, USA). Plasma
concentrations of TAG, FFA, and betahydroxybutyrate (BHB)
were measured with enzymatic tests adapted for the Cobas Mira
autoanalyzer (Cobas Mira, Hoffman La-Roche, Switzerland).
Analysis of Emulsion Effects on Plasma
Concentration Profiles of Paracetamol,
Metabolites, and Gastrointestinal
Hormones
Postprandial delta over baseline (DOB) curves were calculated
from the plasma concentrations of paracetamol, each metabolite
and gastrointestinal hormone. The area over baseline (AOB),
the maximum positive (or negative) amplitude Amax, and the
time-to-maximum amplitude tmax were derived from these DOB
curves by fitting the following power-exponential function to
the data:
Ci (t) = AOBi · ki · βi ·
(
1− e−kit
)βi−1
· e−kit
with i = paracetamol, GLP-1, PYY, TAG, BHB, and FFA.
The final parameter estimates tmax,i and Amax,i were calculated
from tmax,i = log(βi)/ki and Amax,i = Ci(tmax,i). Data fitting
was achieved by Bayesian hierarchical modeling as previously
specified (30). The effect of the LEs on the parameters of plasma
profiles was quantified by the highest posterior density interval
(HPD), also known as credible interval. The interval enclosing
95% of the posterior mass was selected. The effect sizes between
the parameters are presented as median (95% HPD).
Analysis of Emulsion Effects on Food
Intake
A single logistic model was fitted to the food intake curves.
The effect of intervention (emulsion vs. NaCl), emulsion type
(LE1 vs. LE3 and LE4), dose (4 vs. 8mL) and repeated record
(record 1 and record 2) on the logistic model parameters
asymptotic total energy intake EItotal in kcal and time-to-half
total energy intake t1/2 in hours was analyzed by linear mixed
effect models. “Rat” was set as random effect. Observations with
absolute standardized residuals >0.995 quantile of the standard
normal distribution were considered outliers and excluded for
the analysis.
FIGURE 1 | Paracetamol plasma concentration profiles in rats after gastric infusion of 4mL of the three different LEs. Solid and dashed lines show the group median
and the individual concentration curves, respectively (LE1, acid stable LE; LE3, non-redispersible acid unstable LE with solid fat; LE4, redispersible acid unstable LE).
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TABLE 2 | Effect sizes for the emulsion dependent energy intake in rats after gastric infusion of the three different LEs (Effect sizes with the 95% CI interval not including
zero are labeled with*).
Effect sizes, mean (95% CI)
Parameter LE1 (reference) LE3 LE4 8mL dose 2nd record
Emulsion intervention EItotal, kcal 99 (95, 103) 3.4 (1.5, 5.2)* 3.2 (1.1, 4.9)* 0.7 (−0.8, 2.3) 2.0 (0.3, 3.7)*
t1/2, h 4.6 (4.3, 4.9) −0.6 (−0.8, −0.5)* −0.4 (−0.6, −0.2)* −0.3 (−0.4, −0.1)* −0.2 (−0.3, −0.05)*
Subsequent washout days EItotal, kcal 103 (101, 106) −0.7 (−2.2, 0.5) −1.1 (−2.5, 0.3) −0.9 (−1.9, 0.3) −0.3 (−1.5, 0.9)
t1/2, h 4.2 (4.0, 4.3) 0.05 (−0.02, 0.1) 0.06 (−0.01, 0.1) 0.04 (−0.03, 0.1) 0.02 (−0.04, 0.09)
FIGURE 2 | (A) Group median DOB curves and (B) parameter estimates with 95% HPD of the GLP-1, PYY, TAG, BHB, and FFA plasma concentration profiles in the
hepatic portal vein (HPV) in rats after gastric infusion of 4mL of the three different LEs. The DOB curves are grouped by LE (columns) and blood measure (rows). The
concentration profiles have units ρg/mL for GLP-1 and PYY, mmol/L for TAG, µmol/L for BHB and FFA. The boxplots are grouped by parameter (rows) and blood
measure (columns). The values for Amax are equal to the respective concentration profiles. The values for AOB are ρg/mL·h for GLP-1 and PYY, mmol/L·min for TAG,
µmol/L·min for BHB and FFA. The value of tmax is given in min.
RESULTS
A total of four food intake curves, three for the study days
(emulsion) and one for the washout days (NaCl) were excluded
from analysis due to unstable balance readouts. A total of
eight plasma concentration samples, three for gastrointestinal
hormones and five for metabolites were not available due to
missing data samples.
Gastric Emptying
All LEs had a distinct effect on the paracetamol plasma
concentration profiles (Figure 1). Amax was increased for LE3
and LE4 by 0.08 mmol/L (0.05, 0.13 mmol/L) and 0.08 mmol/L
(0.03, 0.1mmol/L), respectively. Accordingly, AOBwas increased
for the acid unstable LE3 and LE4 compared to the acid stable
LE1 by 8 mmol/L·min (3, 10 mmol/L·min) and 6 mmol/L·min
(3, 8 mmol/L·min), respectively. tmax differed only between LE3
and LE4 with tmax of LE4 being later by 21min (3, 47 min).
Food Intake
There was an effect of intervention, emulsion type and dose
on EItotal and t1/2 values. Compared to the washout days,
intervention with LE1 resulted in a decrease of EItotal by −4.3
kcal (95% CI: −6.7, −1.8) and increase in t1/2 by 0.5 h (95% CI:
0.2, 0.6). Intervention with LE3 had no effect on EItotal [−1.4
kcal (95% CI: −3.8, 0.9)], but decreased t1/2 by −0.2 h (95% CI:
−0.4, −0.03). Intervention with LE4 had neither an effect on
EItotal [−1.3 kcal (95% CI: −3.4, 1.1)] nor t1/2 [−0.05 h (95% CI:
−0.2, 0.1)]. Table 2 lists the effects of acid unstable vs. acid stable
emulsions, doubling the dose and repetition of the intervention
on the values for EItotal and t1/2. For LE3 and LE4 an increase of
EItotal and decreased t1/2 was observed. The 8mL dose had no
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effect on EItotal, but decreased t1/2. The second records showed
an increase in the EItotal and accordingly a decrease in the t1/2.
Neither emulsion type nor dose nor record modulated the EItotal
or t1/2 values of the subsequent washout days.
Plasma Concentrations of Gastrointestinal
Hormones and Metabolites
Visual inspection of the DOB curves and boxplots in
Figures 2A,B indicate that the hormone and metabolite
profiles have a similar response to the individual LEs, especially
regarding peak height and relative timing. This LE dependency
was clearly compromised by the large inter-individual variation
observed for the metabolite profiles. LEs had the most distinct
effect on the profiles of PYY (Figure 3). This was equally
well-detectable in the blood of HPV and VC (Table 1). Amax
and tmax of PYY were different among all three LEs. Amax was
highest for LE1 and lowest for LE3. tmax was shortest for LE4
and longest for LE3. AOB of PYY was lower for LE3 and LE4
compared to LE1. The LEs also had differential effects on GLP-1
profiles (Figure 3). This was better reflected in HPV than in VC
blood plasma (Table 3). Amax and AOB of GLP-1 were lower for
LE3 and LE4 compared to LE1. tmax was shorter for LE4 than
LE3. Postprandial TAG and BHB plasma concentration showed
similar patterns for all LEs and differed only in a longer tmax for
LE3 than LE1. Postprandial FFA plasma concentrations did not
exhibit any systematic changes, and no effect of LEs neither for
HPV nor VC blood were detected.
Comparison of Rat and Human Data
The LE dependent gastric emptying dynamic in rats (Figures 1–
3) is clearly recognizable in human data despite the very different
measurement approaches, i.e., indirect marker technique by
paracetamol (rats) vs. direct volume assessment by MRI in
humans (Figure 4): The acid stable LE1 showed slow and steady
emptying. In contrast, the acid-unstable LE3 and LE4 showed
immediate emptying. The maximum hormonal response was
reached earlier in rats than in humans (Figure 5A). Nevertheless,
the LE dependency of plasma hormone levels was in good
agreement between rats and humans. PYY and GLP-1 responses
were greatest for LE1 and lowest and most delayed for LE3
(Figure 5B and Table 4). Further, the effect on food intake in
rats are consistent with patterns in the emulsion-dependent
postprandial hunger and fullness scores of the human subjects
(30). Subjects reported lowest hunger and highest fullness scores
for LE1, which agrees with the lowest EItotal and longest t1/2 in
rats for this emulsion.
DISCUSSION
Three LEs with different gastric stability were tested in
randomized cross-over studies to establish a human-rat model
for dietary lipid digestion. In both species food intake and
release of satiating GI hormones was correlated to the design of
the LEs, thus providing a link between food structure and fat
digestion. This animal study demonstrates that an acid stable
lipid emulsion (LE1) increased satiating responses including
plasma GLP1 and PYY release. It also reduced gastric emptying
FIGURE 3 | Schematic of the effects of emulsion stability and redispersibility
on plasma concentration profiles of GLP-1 and PYY in rats after gastric
infusion of 4mL of the three different LEs. The arrows indicate the decrease
and shift in peak concentration due to the changes in emulsion stability and
redispersibility.
rates compared with acid unstable emulsions (LE3, LE4). These
physiological findings are consistent with previously published
(30) human data. Thus, even though the same amount of fat
was administered with each single emulsion, the physiological
responses in rats and humans differed in similar fashion.
The results in both rats and humans can be attributed to
differences in emulsion structure formed during digestion as
previously observed in vitro (33, 35) and in vivo (14, 15, 36).
The magnitude of the hormonal responses was associated to
the acid stability and redispersibility of the emulsions and
thus likely to be dependent on the availability of lipids for
digestion (LE1 > LE4 > LE3 in decreasing order). Rats
may therefore be a viable model for gastrointestinal human
fat processing.
We assessed gastric emptying by measuring the paracetamol
plasma concentration after gastric infusion of the LEs.
Paracetamol is a hydrophilic compound known for its fast
and complete absorption. Its plasma level therefore represents
the emptying rate of the aqueous phase of LEs (37). LE1 exhibited
the slowest increase in paracetamol concentration indicating
simultaneous emptying of the aqueous and lipid phase as can
be expected for an acid stable emulsion. The steady release of
small fat droplets into the small intestine is known to slow gastric
emptying (13, 38). The same emptying characteristics of LE1
were previously identified in humans (14, 15).
The acid-unstable emulsions LE3 and LE4 exhibited an
instantaneous and rapid increase in paracetamol plasma
concentration with peak concentrations at 30 and 60min,
respectively. Both LEs destabilize in the gastric environment
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TABLE 3 | Effect of acid stability and redispersibility on gastrointestinal hormone profiles in rats after gastric infusion of 4mL of the three different LEs (only parameters
exhibiting effect sizes with 95% HPDs not including zero are listed in this table.
Hormone Blood Parameter Median (95% HPD) Emulsion effect
GLP-1 HPV 1Amax31, pg/mL −57 (−87 to −28) Acid instability (LE3, LE4)
1Amax41, pg/mL −37 (−72 to −2) → lower GLP-1 peak
1tmax43, min −68 (−142 to −21) Acid instability and no redispersibility (LE3)
→ delayed GLP-1 peak
1AOB31, pg/mL·h −155 (−232 to −25) Acid instability (LE3, LE4)
1AOB41, pg/mL·h −194 (−256 to −114) → less GLP-1 release
VC 1Amax31, pg/mL −19 (−28 to −11) see HPV
1Amax41, pg/mL −17 (−26 to −10) see HPV
1AOB41, pg/mL·h −39 (−59 to −13) Acid instability and redispersibilty (LE4)
→ less GLP-1 release
PYY HPV 1Amax31, pg/mL −303 (−374 to −222) Acid instability (LE3, LE4)
1Amax41, pg/mL −202 (−283 to −131) → lower PYY peak.
1Amax43, pg/mL 91 (30 to 162) No redispersibility (LE3)→ further decrease in PYY peak
1tmax31, min 60 (34 to 87) Acid instability and no redispersibility (LE3)
→ delayed PYY peak
1tmax41, min −30 (−44 to −11) Acid instability and redispersibility (LE4)
1tmax43, min −90 (−123 to −65) → earlier PYY peak
1AOB31, pg/mL·h −418 (−703 to −94) Acid instability (LE3, LE4)
1AOB41, pg/mL·h −437 (−737 to −228) → less PYY release
VC 1Amax31, pg/mL −240 (−332 to −166) see HPV
1Amax41, pg/mL −166 (−266 to −108) see HPV
1Amax43, pg/mL 66 (8 to 116) see HPV
1tmax31, min 65 (35 to 123) see HPV
1tmax41, min −26 (−47 to −4) see HPV
1tmax43, min −94 (−142 to −50) see HPV
1AOB31, pg/mL·h −354 (−579 to −104) see HPV
1AOB41, pg/mL·h −331 (−544 to −163) see HPV
TAG HPV 1tmax31, min 53 (12 to 99) Acid instability and no redispersibility (LE3)
BHB VC 1tmax31, min 35 (0.5 to 76) → delayed TAG and BHB peak
1Amax41, 1tmax41, 1AOB41 are the effect sizes of the maximum amplitude (Amax ), the time-to-maximum amplitude (tmax ) and area over baseline (AOB) between the acid unstable
LE4 and the acid stable LE1. All other effect sizes are encoded accordingly. 95% HPD: 95% highest posterior density interval. LE1: acid stable LE; LE3: non-redispersible acid unstable
LE with solid fat, LE4: redispersible acid unstable LE, CCK: cholecystokinin, PYY: peptide YY, GLP-1: glucagon-like peptide 1, BHB: betahydroxybutyrate, HPV: hepatic portal vein, VC:
vena cava.).
resulting in an increased droplet size and hence a decreased
specific surface area resulting in a reduced rate of lipolysis
(39, 40). The previous human MRI study confirmed that LE3
forms indispersible semi-solid fat particles whilst LE4 forms a
creamed redispersible lipid layer inside the stomach (14). These
processes lead to a rapid emptying of the total gastric content
which includes both the faster emptying of the aqueous phase
and fat phase (15). The semi-solid state of LE3 is most likely an
additional factor that impaired lipolysis kinetics (41). Kalogeris
et al. observed that gastric emptying rate is inversely correlated
with meal nutrient density in rats (42) and results from this study
indicate that a similar effect can be achieved by different food
structuring. Based on our lipid emulsion systems we showed that
in agreement with human studies LE structuring alters gastric
emptying rates in rats.
The effect of LE stability on the satiating hormones GLP-
1 and PYY was analyzed by sampling blood from both the
HPV and VC. This challenging procedure was motivated
by the fact that intact GLP-1 is rapidly degraded during
passage across the hepatic bed by DPP IV associated with
hepatocytes (43). A previous study in rats showed that the
GLP-1 concentration in the HPV was always higher than in
the VC (44). Nevertheless, the effect of LE stability on GLP-
1 concentration profiles was detectable in plasma from both
blood vessels. Hence hepatic portal vein catheterization is not
strictly required for the detection of LE-related effects on GLP-
1 concentrations. Moreover, the good detectability of LE effects
even at lower concentrationsmay be attributed to the numerically
robust Bayesian hierarchical fit procedure. This allowed for the
extraction of dynamic features of plasma profiles, which are
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FIGURE 4 | Paracetamol plasma concentration profiles in rats and gastric content emptying curves in humans after intake of the three different LEs. The data is
grouped by LE (columns) and species (rows). Solid and dashed lines show the group median and individual curves, respectively.
otherwise impossible to detect using the widely applied area
under the curve (AUC) measure.
The hormonal plasma concentration profiles revealed that the
acid stable emulsion LE1 stimulated the greatest release of GLP-
1 and PYY. This is likely due to the constant emptying of the
small fat droplets into the duodenum resulting in the highest
rate of lipolysis and subsequent fatty acid sensing. LE3 caused
delayed GLP-1 and PYY concentration peaks and a smaller
overall hormone release compared to LE4 and LE1. This may
be attributed to its semi-solid state impairing lipolysis and thus
fatty acid sensing. There are no previous studies that analyzed the
effects of emulsion stability and emptying on satiating hormones
in rats. Lipolysis kinetics were, however, described to depend on
lipid droplet size also in rats (45). Furthermore, lipid induced
gastrointestinal hormone release has been previously investigated
(26, 46). An increase in plasma PYY after intraduodenal and
intraileal oleic acid administration to rats was reported. These
findings using oleic acid administration, however, contrast results
from experiments using the vascularly perfused rat ileum or
colon (24, 25, 27). These indicated that there was no hormone
response upon perfusion with oleic acid, but a response was noted
with the bile salt taurocholate. The authors postulated that an
indirect GLP-1 and PYY release mechanism involving bile salts
could provide one possible explanation. Alternatively, it may be
relevant whether the enteroendocrine cells are exposed to oleic
acid from the intestinal lumen or from the blood.
The observed LE-dependent satiating hormone responses and
gastric emptying patterns fit the lipid emulsion effects on short-
term food intake. Rats consumed less food after infusion of LE1
compared to LE3 and LE4. Interestingly, however, circulating
fat metabolites were only marginally influenced by emulsion
stability. TAG and BHB plasma peak concentrations were slightly
delayed for LE3, but no emulsion effect was found for FFA
plasma concentrations. Both findings are in agreement with
previous observations in humans (47). This could indicate that
fat metabolism in relation to rapeseed oil is largely uncoupled
from lipolysis kinetics, which in turn suggests that mainly gastric
emulsion stability modulates gastric emptying rate and lipolysis
kinetics in rats. These modulations may influence hormonal
responses directly by fatty acid sensing or also indirectly by the
release of other substances such as bile salts.
The observed effects of emulsion stability on rat
gastrointestinal physiology were largely in agreement with
the effects previously observed for humans. To allow for
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FIGURE 5 | (A) Estimated group average DOB curves and (B) parameter estimates of the GLP-1, PYY, TAG, BHB, and FFA plasma concentration profiles in rats and
humans after intake of the three different LEs. (A) The DOB curves are grouped by LE (columns) and blood parameter (rows). Solid and dashed black lines indicate
group average rat and human DOB curves, respectively. The concentration profiles have units ρg/mL for GLP-1 and PYY, mmol/L for TAG, µmol/L for BHB and FFA.
(B) The boxplots are grouped by parameter (rows) and blood measure (columns). The values for Amax are equal to the respective concentration profiles. The values
for AOB are ρg/mL·h for GLP-1 and PYY, mmol/L·min for TAG, µmol/L·min for BHB and FFA. The value of tmax is given in min.
a more detailed visual comparison, rat and human plasma
concentration profiles and gastric emptying curves were overlaid
or displayed side-by-side (Figures 4, 5). Only VC rat blood
measures are shown for better comparison with humans. Gastric
emptying in humans and rats followed similar patterns, even
though in rats it was measured indirectly via the paracetamol
plasma concentrations. The acid stable LE1 showed slow and
steady emptying, while the acid unstable LE3 and LE4 showed
immediate emptying. Thus, acid unstable emulsions undergo
the same destabilization in both rats and humans, i.e., increased
droplet size and creaming. Also, plasma hormone levels were
in good agreement between rats and humans. PYY and GLP-1
responses were largest for LE1, indicating increased lipolysis
kinetics due to smaller lipid droplets. LE3 resulted in a delayed
satiating response. This can probably be attributed to formation
of semi-solid fat particles that are not redispersible and delay
lipolysis. Although inter-emulsion responses were similar in
rats and humans, corresponding plasma concentration profiles
differed in dynamics. Themaximum response was reached earlier
in rats than in humans, which is most likely due to their overall
faster metabolism. In humans, plasma TAG concentrations
were significantly lower for LE3 compared to LE1 and LE4.
This finding was not supported in the rat study, indicating that
intraluminal lipolysis of LE3 and enterocyte reesterification
of fatty acids are more efficient in rats than in humans. This
may originate from a superimposed effect of an overall faster
metabolism and smaller semi-solid fat particles generated in
rats resulting in a higher surface to volume ratio easing luminal
lipolysis. Such smaller fat particles might derive from the lower
fat amount administered or higher shear forces generated in
the rat stomach due to the smaller pylorus. Generally, more
effects of emulsion type on hormonal responses were detected
in rats. This may be explained by (i) the smaller inter-individual
differences, (ii) the more central location of blood sampling,
and (iii) a more robust modeling of the faster hormone profile
response in rats. Interestingly, postprandial FFA increased in
rats, which is presumably because some fatty acids escaped the
lipoprotein lipase-mediated uptake of TAG into tissues, whereas
FFA partly decreased in humans. This decrease in FFA, however,
is commonly observed in humans after breakfast and presumably
due to an insulin-induced inhibition of lipolysis from adipose
tissue (48).
Overall the dynamics in rats and humans showed surprisingly
similar characteristics for both rats and humans. Key satiating
physiological signals specifically modulated by these systems
show similar characteristics with differences most prominent
in timing of peak amplitudes and clearance times. Given
the study hypothesis and design, the underlying reasons and
mechanisms for these differences cannot be investigated within
this study design. However, changes in short-term energy intake
in rats reflect the changes in self-reported sensations of hunger
and fullness in humans. These findings therefore support the
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TABLE 4 | Comparing the effects of emulsions stability and redispersibility on gastrointestinal hormone profiles between rats and humans after intake of the three different
LEs (LE1, acid stable LE; LE3, non-redispersible acid unstable LE with solid fat; LE4, redispersible acid unstable LE; CCK, cholecystokinin; PYY, peptide YY; GLP-1,
glucagon-like peptide 1; BHB, betahydroxybutyrate; FFA, free fatty acids).
Measure Effect Rat Human
GLP-1 1Amax31, pg/mL −19 (−28 to −11) −3.0 (−6.4, 0.2) Acid instability (LE3, LE4)
1Amax41, pg/mL −17 (−26 to −10) −2.6 (−5.4, 0.5) → lower GLP-1 peak in rats and in humans
1AOB41, pg/mL·h −39 (−59 to −13) −3 (−57, 75) Acid instability and redispersibility (LE4)
→ less GLP-1 release only in rats
PYY 1Amax31, pg/mL −240 (−332 to −166) −47 (−79, −19) Acid instability (LE3, LE4)
1Amax41, pg/mL −166 (−266 to −108) −44 (−79, −15) → lower PYY peak in rats and humans
1tmax41, min −26 (−47 to −4) −178 (−369, −39) Acid instability and redispersibility (LE4)
1tmax43, min −94 (−142 to −50) −336 (−802, −31) → earlier PYY peak in rats and humans
1AOB31, pg/mL·h −354 (−579 to −104) −343 (−912, 522) Acid instability and no redispersibility (LE3)
→ less PYY release only in rats
1tmax31, min 65 (35 to 123) 151 (−132, 599) Acid instability and no redispersibility (LE3)
→ delayed PYY peak only in rats
TAG 1tmax31, min 53 (12 to 99) −146 (−352, 11) Acid instability and no redispersibility (LE3)
→ earlier TAG peak only in rats
dAmax31 −0.1 (−0.2, 0.1) −0.4 (−0.6, −0.2) Acid instability and no redispersibility (LE3)
dAOB31 4 (−35, 47) −236 (−439, −105) → lower TAG peak and release only in humans
BHB 1tmax31, min 35 (0.5 to 76) 42 (−169, 216) Acid instability and no redispersibility (LE3)
→ delayed BHB peak only in rats
FFA No emulsion effect neither in rats nor in humans
use of rat models for reliable and relevant in vivo studies
on the control of satiation and energy intake by tailored
lipid systems.
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